Successful use of canakinumab in a patient with resistant Behçet's disease

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Cantarini, L ^a   Vitale, A ^a   Borri, M ^b   Galeazzi, M ^a   Franceschini, R ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CANAKINUMAB; CYCLOSPORIN A; ETANERCEPT; FIBRINOGEN; HLA B51 ANTIGEN; INFLIXIMAB; INTERLEUKIN 1BETA; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SERUM AMYLOID A; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; BACTERIAL ENDOCARDITIS; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENITAL ULCER; GRANULOMA ANNULARE; HUMAN; INTESTINE ULCER; LETTER; LEUKOCYTOSIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PRURITUS; RECURRENT INFECTION; RELAPSE; REMISSION; SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA; DRUG RESISTANCE; IMMUNOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874983325     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE Criteria for Diagnosis of Behçet's disease. Lancet 1990; 35: 1078-80.
2. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
3. ALEXOUDI I, KAPSIMALI V, VAIOPOULOS A, KANAKIS M, VAIOPOULOS G Evaluation of current therapeutic strategies in Behçet's disease. Clin Rheumatol 2011; 30: 157-63.
4. GUL A Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005; 4: 81-3.
5. BOTSIOS C, SFRISO P, FURLAN A, PUNZI L, DINARELLO CA Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008; 149: 284-6.
6. ONAL S, KAZOKOGLU H, KOC A et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 2011; 129: 288-94.
7. Cantarini L, TINAZZI I, CARAMASCHI P, BELLISAI F, BROGNA A, GALEAZZI M Safety and efficacy of etanercept in children with juvenile-onset Behçets disease. Int J Immunopathol Pharmacol 2009; 22: 551-5.
8. PIPITONE N, OLIVIERI I, PADULA A et al. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008; 59: 285-90.
9. ACCORINTI M, PIRRAGLIA MP, PAROLI MP, PRIORI R, CONTI F, PIVETTI-PEZZI P Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007; 51: 191-6.
10. GÜL A, TUGAL-TUTKUN I, DINARELLO CA et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012; 71: 563-6.